Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital » 07:50
11/03/22
11/03
07:50
11/03/22
07:50
KURA

Kura Oncology

$15.61 /

-0.38 (-2.38%)

, BMY

Bristol-Myers

$77.46 /

-0.26 (-0.33%)

, HTGC

Hercules Capital

$14.28 /

-0.245 (-1.69%)

Kura Oncology (KURA)…

Kura Oncology (KURA) announced a $25 million equity investment from Bristol Myers Squibb (BMY) and a term loan facility with access to up to $125 million from Hercules Capital, Inc. (HTGC). If the term loan is fully drawn, proceeds from these two transactions together with existing cash are expected to fund Kura's current operating plan into 2026. Kura has agreed to sell 1,370,171 shares to Bristol Myers Squibb at a price of $18.25 per share for gross proceeds of $25 million. The shares of common stock were offered and sold to Bristol Myers Squibb in a registered direct offering. In connection with the equity investment, Bristol Myers Squibb will appoint a member to Kura's Global Steering Committee. Kura will maintain full ownership and control of its programs and operations. Under the terms of the loan agreement with Hercules Capital, $10 million will be drawn immediately after closing and an additional $15 million is immediately available to Kura at its sole discretion. Kura may draw an additional $75 million in two separate tranches upon achievement of near-term clinical milestones. An additional $25 million may be drawn in a fourth tranche, subject to the approval of Hercules Capital. The loan bears an initial interest rate of 8.65% and adjusts with future changes in the prime rate. Kura will pay interest only for the first 24 months, extendable to up to 48 months on achievement of certain milestones. The loan matures 60 months from closing in November 2027.

ShowHide Related Items >><<
KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

HTGC Hercules Capital
$14.28 /

-0.245 (-1.69%)

BMY Bristol-Myers
$77.46 /

-0.26 (-0.33%)

KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
BMY Bristol-Myers
$77.46 /

-0.26 (-0.33%)

11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
10/31/22 Guggenheim
2seventy Bio initiated with a Buy at Guggenheim
10/12/22 Barclays
Bristol-Myers price target lowered to $66 from $69 at Barclays
10/10/22 Guggenheim
Guggenheim downgrades Bristol-Myers ahead of 'large and pricey' Phase 3 trials
HTGC Hercules Capital
$14.28 /

-0.245 (-1.69%)

10/03/22 Piper Sandler
Hercules Capital price target lowered to $13 from $16 at Piper Sandler
07/29/22 Oppenheimer
Hercules Capital downgraded to Perform from Outperform at Oppenheimer
07/29/22 Oppenheimer
Hercules Capital downgraded to Perform from Outperform at Oppenheimer
06/28/22 Piper Sandler
Hercules Capital price target lowered to $15.50 from $18.50 at Piper Sandler
KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

HTGC Hercules Capital
$14.28 /

-0.245 (-1.69%)

BMY Bristol-Myers
$77.46 /

-0.26 (-0.33%)

BMY Bristol-Myers
$77.46 /

-0.26 (-0.33%)

KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

BMY Bristol-Myers
$77.46 /

-0.26 (-0.33%)

BMY Bristol-Myers
$77.46 /

-0.26 (-0.33%)

Hot Stocks
Kura Oncology expects cash to fund operations into 2026 » 07:38
11/03/22
11/03
07:38
11/03/22
07:38
KURA

Kura Oncology

$15.61 /

-0.38 (-2.38%)

Cash, cash equivalents…

Cash, cash equivalents and short-term investments totaled $427.8 million as of September 30, 2022, compared with $518.0 million as of December 31, 2021. Management believes that cash, cash equivalents and short-term investments, plus cash from the term loan facility from Hercules, if fully drawn, will be sufficient to fund its current operating plan into 2026.

ShowHide Related Items >><<
KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

Earnings
Kura Oncology reports Q3 EPS (53c), consensus (56c) » 07:38
11/03/22
11/03
07:38
11/03/22
07:38
KURA

Kura Oncology

$15.61 /

-0.38 (-2.38%)

"We are very proud…

"We are very proud to announce that our abstract reporting updated data from the KOMET-001 trial of ziftomenib has been accepted for oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting in December," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "We continue to have strong conviction in ziftomenib and its potential to be a best-in-class menin inhibitor. Our confidence is supported by a growing body of clinical data, and we look forward to sharing a comprehensive update on the program at ASH. Earlier this morning, we also announced a $25 million equity investment from Bristol Myers Squibb and a $125 million term loan facility from Hercules Capital," Dr. Wilson continued. "If the term loan facility is fully drawn, proceeds from these two transactions, together with our existing cash, are expected to fund our current operating plan into 2026, enabling us to advance ziftomenib as well as our farnesyl transferase inhibitor programs through important, clinical-stage inflection points that we believe will create meaningful value for patients and shareholders."

ShowHide Related Items >><<
KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

KURA Kura Oncology
$15.61 /

-0.38 (-2.38%)

Hot Stocks
Kura reports preliminary proof of mechanism in Phase 1/2 trial of tipifarnib » 07:42
10/26/22
10/26
07:42
10/26/22
07:42
KURA

Kura Oncology

$16.53 /

-0.355 (-2.10%)

Kura Oncology reported…

Kura Oncology reported proof of mechanism in KURRENT-HN, the Company's Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma, HNSCC. The preliminary data are being presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Barcelona. In a poster entitled, "HNSCCs overexpressing wild-type HRAS are sensitive to combined tipifarnib and alpelisib treatment," Kura highlights a patient with stage III squamous cell carcinoma of the tonsil, including a PIK3CA mutation and HRAS overexpression, who has achieved a durable partial remission on study. The 35-year-old patient enrolled in KURRENT-HN after failing two prior treatments, experienced an 81% reduction in target lesions after one cycle of tipifarnib and alpelisib and an 84% reduction after three cycles. As of September 14, 2022, the patient continued on study for more than 27 weeks. Treatment-related adverse events in the study have been consistent with the known safety profiles of each drug and are manageable, with no dose-limiting toxicities reported to date.

ShowHide Related Items >><<
KURA Kura Oncology
$16.53 /

-0.355 (-2.10%)

KURA Kura Oncology
$16.53 /

-0.355 (-2.10%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$16.53 /

-0.355 (-2.10%)

KURA Kura Oncology
$16.53 /

-0.355 (-2.10%)

Conference/Events
Kura Oncology management to meet with Cantor Fitzgerald » 18:25
09/28/22
09/28
18:25
09/28/22
18:25
KURA

Kura Oncology

$13.42 /

+0.71 (+5.59%)

In conjunction with the…

In conjunction with the Cantor Oncology, Hematology & HemeOnc Conference, Cantor Fitzgerald Biotechnology Analyst Watsek holds an Investor Group Dinner with President & CEO Wilson and SVP DeSpain in New York on September 28 at 6:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

Conference/Events
Kura Oncology management to meet with Cantor Fitzgerald » 17:55
09/28/22
09/28
17:55
09/28/22
17:55
KURA

Kura Oncology

$13.42 /

+0.71 (+5.59%)

In conjunction with the…

In conjunction with the Cantor Oncology, Hematology & HemeOnc Conference, Cantor Fitzgerald Biotechnology Analyst Watsek holds an Investor Group Dinner with President & CEO Wilson and SVP DeSpain in New York on September 28 at 6:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

KURA Kura Oncology
$13.42 /

+0.71 (+5.59%)

Conference/Events
Kura Oncology management to meet with Cantor Fitzgerald » 15:55
09/28/22
09/28
15:55
09/28/22
15:55
KURA

Kura Oncology

$13.49 /

+0.785 (+6.18%)

In conjunction with the…

In conjunction with the Cantor Oncology, Hematology & HemeOnc Conference, Cantor Fitzgerald Biotechnology Analyst Watsek holds an Investor Group Dinner with President & CEO Wilson and SVP DeSpain in New York on September 28 at 6:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KURA Kura Oncology
$13.49 /

+0.785 (+6.18%)

KURA Kura Oncology
$13.49 /

+0.785 (+6.18%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$13.49 /

+0.785 (+6.18%)

KURA Kura Oncology
$13.49 /

+0.785 (+6.18%)

Conference/Events
Kura Oncology management to meet with Cantor Fitzgerald » 04:55
09/28/22
09/28
04:55
09/28/22
04:55
KURA

Kura Oncology

$12.70 /

+0.16 (+1.28%)

In conjunction with the…

In conjunction with the Cantor Oncology, Hematology & HemeOnc Conference, Cantor Fitzgerald Biotechnology Analyst Watsek holds an Investor Group Dinner with President & CEO Wilson and SVP DeSpain in New York on September 28 at 6:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KURA Kura Oncology
$12.70 /

+0.16 (+1.28%)

KURA Kura Oncology
$12.70 /

+0.16 (+1.28%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$12.70 /

+0.16 (+1.28%)

KURA Kura Oncology
$12.70 /

+0.16 (+1.28%)

Conference/Events
Kura Oncology management to meet with Cantor Fitzgerald » 15:28
09/22/22
09/22
15:28
09/22/22
15:28
KURA

Kura Oncology

$12.43 /

+0.42 (+3.50%)

In conjunction with the…

In conjunction with the Cantor Oncology, Hematology & HemeOnc Conference, Cantor Fitzgerald Biotechnology Analyst Watsek holds an Investor Group Dinner with President & CEO Wilson and SVP DeSpain in New York on September 28 at 6:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KURA Kura Oncology
$12.43 /

+0.42 (+3.50%)

KURA Kura Oncology
$12.43 /

+0.42 (+3.50%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$12.43 /

+0.42 (+3.50%)

KURA Kura Oncology
$12.43 /

+0.42 (+3.50%)

Conference/Events
Kura Oncology management to meet with Cantor Fitzgerald » 15:23
09/22/22
09/22
15:23
09/22/22
15:23
KURA

Kura Oncology

$12.43 /

+0.415 (+3.46%)

In conjunction with the…

In conjunction with the Cantor Oncology, Hematology & HemeOnc Conference, Cantor Fitzgerald Biotechnology Analyst Watsek holds an Investor Group Dinner with President & CEO Wilson and SVP DeSpain in New York on September 28 at 6:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
KURA Kura Oncology
$12.43 /

+0.415 (+3.46%)

KURA Kura Oncology
$12.43 /

+0.415 (+3.46%)

07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
07/12/22 Cantor Fitzgerald
Kura Oncology initiated with an Overweight at Cantor Fitzgerald
02/15/22 Jefferies
Kura Oncology initiated with a Buy at Jefferies
11/26/21 Credit Suisse
Kura Oncology price target lowered to $21 from $40 at Credit Suisse
KURA Kura Oncology
$12.43 /

+0.415 (+3.46%)

KURA Kura Oncology
$12.43 /

+0.415 (+3.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.